McLaughlin Selected as Neurorehabilitation and Restorative Training Network K12 Scholar on Grant from NIH/NICHD
Study title: Precision medicine in pediatric patients with Cerebral Palsy
Matthew J. McLaughlin, MD, Pediatric Physical Medicine/Rehabilitation, has been selected as a Neurorehabilitation and Restorative Training Network (NRNTN) K12 Scholar on a two-year, $250,000 grant from the National Center for Medical Rehabilitation Research (NIH/NICHD).
Dr. McLaughlin and his study team will be working to improve the understanding of baclofen metabolism, distribution and response in pediatric patients with Cerebral Palsy as a part of the GOLDILOKs framework developed by Clinical Pharmacology. Baclofen is the most commonly prescribed oral medication for spasticity, but little is known about its efficacy or distribution into the central nervous system.
This study, called “Precision medicine in pediatric patients with Cerebral Palsy,” looks at plasma to CSF levels to determine how much baclofen crosses the blood-brain barrier and also correlates plasma concentrations to how much clinical response is seen.
“My long-term goal is to establish an independent precision medicine-based research program that improves functional outcomes in neurorehabilitation patients by investigating inter-individual differences in dose-exposure-response relationships,” said Dr. McLaughlin. “This is the first study to utilize the innovative approach of linking precision medicine to corresponding functional outcomes in neurorehabilitation patients. These aims, conducted in independent cohorts of children, construct a model that allows improved dosing recommendations for pediatric patients with functional impairments, ultimately improving the way in which providers prescribe therapeutic interventions for patients requiring neurorehabilitation.”
Children’s Mercy Kansas City is ranked as one of “America's Best Children's Hospitals” in nine specialties rated by U.S. News & World Report and has received MagnetTM recognition for excellence in nursing services five consecutive times. With 386 licensed beds and a medical staff of more than 750 pediatric subspecialists, we care for children from all 50 states and from around the world. In addition, our leadership in pediatric genomic medicine and individualized pediatric therapeutics is driving research and innovation in neonatology, nephrology, endocrinology, gastroenterology, neurology, heart, cancer and other subspecialties to transform outcomes for children. Children’s Mercy also is nationally recognized for innovation in psychosocial care and creating a family-centered environment focused on the unique needs of hospitalized children and their families. Our love for children powers everything we do, inspiring our research, innovations and our everyday care. Because love has no limits. And with it, neither do we.